BRISTOL-MYERS SQUIBB COMPANY Treasury Stock Acquired, Average Cost Per Share
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Treasury Stock Acquired, Average Cost Per Share of $28.29 per share for the 3-month period ending 2011-06-30, per its 10-Q filed 2011-07-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2011-07-28
- BRISTOL-MYERS SQUIBB COMPANY treasury stock acquired, average cost per share for the quarter ending 2011-06-30 was $28.29, a 19.12% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock acquired, average cost per share for the quarter ending 2011-03-31 was $25.74.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock acquired, average cost per share for the quarter ending 2010-06-30 was $23.75.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock acquired, average cost per share for fiscal 2010 was $25.50.
| Period end | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 6 month | Treasury Stock Acquired, Average Cost Per Share 12 month |
|---|---|---|---|
| 2011-06-30 | $28.29 10-Q · filed 2011-07-28 | $27.32 10-Q · filed 2011-07-28 | |
| 2011-03-31 | $25.74 10-Q · filed 2011-04-28 | ||
| 2010-12-31 | $25.50 10-K · filed 2011-02-18 | ||
| 2010-06-30 | $23.75 10-Q · filed 2011-07-28 | $23.75 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |